Evidence

Review and download supporting evidence. Includes the full guideline if available.

Supporting evidence

Other supporting evidence
Methods ^{PDF 351 KB} 13 August 2024
Economic analysis
Economic model report ^{PDF 1.85 MB} 13 August 2024
Evidence review
A: Prognostic factors for progression of non-proliferative diabetic retinopathy ^{PDF 879 KB} 13 August 2024
B: Different thresholds or criteria for starting treatment for non-proliferative diabetic retinopathy, proliferative diabetic retinopathy, and diabetic macular oedema ^{PDF 1.11 MB} 13 August 2024
C: Effectiveness of intensive treatments to lower blood glucose levels ^{PDF 1.16 MB} 13 August 2024
D: Effectiveness of lipid modification therapies and antihypertensive medicines ^{PDF 1.19 MB} 13 August 2024
E: Effectiveness and acceptability of anti-vascular endothelial growth factor agents and laser photocoagulation (alone or in combination) for the treatment of non-proliferative and proliferative diabetic retinopathy ^{PDF 1.3 MB} 13 August 2024
F: Vitrectomy ^{PDF 1.7 MB} 13 August 2024
G: Effectiveness and acceptability of intravitreal steroids, macular laser and anti-vascular endothelial growth factor agents for treating diabetic macular oedema ^{PDF 5.06 MB} 13 August 2024
H: Clinical features for switching or stopping treatment for proliferative diabetic retinopathy or diabetic macular oedema ^{PDF 903 KB} 13 August 2024
I: Treatments before, during or after cataract surgery ^{PDF 1.19 MB} 13 August 2024
J: Effectiveness of different monitoring frequencies ^{PDF 779 KB} 13 August 2024
K: Diagnostic accuracy of ultrawide-field fundus photography and optical coherence tomography ^{PDF 843 KB} 13 August 2024
Evidence reviews – August 2024